Sutro Bio - STRO Net earnings per share for the last four quarters

Official company branding of Sutro Bio (STRO)

The price history of Sutro Biopharma, Inc. (STRO) reflects an EPS TTM of 51.30. Sutro Biopharma, Inc. (STRO) attracts leading oncobiologists by offering them cutting-edge laboratories and stock options. The business is currently focused on developing less toxic targeted therapies and is in the clinical trial stage. However, geopolitical instability and the severance of scientific ties create risks for the timely completion of trials for new treatment methods.

Sutro Biopharma (STRO) Earnings per share for the last twelve months: for the period 02/11/2024 - 11/15/2026

STRO (Sutro Biopharma): analytical breakdowns and indicator data

Initial company analysis:STRO, Sutro Bio
Mass-produced product of sutrobio.com

This metric measures the annual change in net profit per share over the last twelve months, reflecting the efficiency of profit generation relative to inflationary pressure and rising costs. By analyzing the current EPS YoY TTM trend, an investor assesses the margin stability of Sutro Biopharma, Inc. (STRO), considering the risks of dependence on external contract manufacturers when scaling drug production.

Direct competitors

Earnings per share for the trailing year IBRX (ImmunityBio)|IMCR: Net earnings per share (EPS TTM)|JANX - Net earnings per share for the last four quarters|Earnings per share for the last twelve months arcusbio.com|Net earnings per share for the last 12 months zymeworks.com (ZYME)|Earnings per share for the last twelve months Tango Therapeutics Inc (TNGX)|Net earnings per share for the last 12 months Iovance IOVA|Immatics NV - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Xencor Inc. XNCR|CMPX - Earnings per share for the last twelve months|REPL (replimune.com) - Earnings per share for the last 12 months|Lyell Pharma (LYEL) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Innate Pharma, S.A. (IPHA)|Net earnings per share for the last 12 months PYXS|CGEN - Net earnings per share for the trailing year|Net earnings per share for the last 12 months IOBT (IO Biotech Corp)|Earnings per share for the last four quarters INKT|Net earnings per share (EPS TTM) HOWL (Werewolf Therapeutics)|Earnings per share for the trailing year IMMX|alxoncology.com - Net earnings per share (EPS TTM)|Earnings per share for the trailing year CUE (Cue Biopharma)|PDS Biotechnology Corp (PDSB) - Earnings per share for the last twelve months|Sonnet BioTherapeutics Holdings, Inc. - Earnings per share for the trailing year|MAIA (MAIABiotech.com) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Liminatus Pharma Inc.|Earnings per share for the last twelve months lavatherapeutics.com (LVTX)|NXTC: Earnings per one share for the last 12 months|Leap Therapeutics - Net earnings per share for the last 12 months|Intensity Tx (INTS) - Net earnings per one share for the last twelve months|SNSE - Earnings per share for the last twelve months|Theriva Biologics - Earnings per share for the last four quarters|Gritstone Bio (GRTS) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Kineta, Inc. (KA)|Net earnings per share for the last 12 months NEXI|TSBX: Earnings per share for the trailing year|Net earnings per share (EPS TTM) VCNX|HARP: Earnings per one share for the last 12 months